Sabine Mueller, MD, PhD

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Sabine Mueller, MD, PhD sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 5 currently recruiting 4 completed early-phase tilt top decile by trial count

Sabine Mueller, MD, PhD: 12 sponsored US clinical trials, 5 recruiting.

Sabine Mueller, MD, PhD sponsors 12 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Recurrent Malignant Glioma, with 2 trials.

Top-decile sponsor footprint

Sabine Mueller, MD, PhD ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

12 total, page 1 of 1

RECRUITING Phase 2

Study of Novel Therapies for Young People With Recurrent/Progressive Atypical Teratoid Rhabdoid Tumor (ATRT)

NCT07447076
RECRUITING Phase 1

Intra-Tumoral Injections of Natural Killer Cells for Recurrent Malignant Pediatric Brain Tumors

NCT05887882
RECRUITING Phase 2

Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

NCT05465174
RECRUITING Phase 1

ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

NCT04732065
RECRUITING Phase 1

Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults

NCT04323046
ACTIVE NOT RECRUITING Early Phase 1

Fimepinostat in Treating Brain Tumors in Children and Young Adults

NCT03893487
NOT YET RECRUITING Phase 1

Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

NCT07346157
NOT YET RECRUITING Phase 1

Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)

NCT07389278
COMPLETED Phase 1

MTX110 by Convection-Enhanced Delivery in Treating Participants With Newly-Diagnosed Diffuse Intrinsic Pontine Glioma

NCT03566199
COMPLETED Phase 1

CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)

NCT03086616
COMPLETED Phase 1

Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT

NCT02962167
COMPLETED Phase 1

H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas

NCT02960230

Phase Distribution

PhaseTrial count
Phase 1 10
Phase 2 2

Therapeutic Areas

Recurrent Malignant Glioma 2
Recurrent Glioblastoma 2
Glioblastoma 2
Medulloblastoma, Childhood, Recurrent 1
Recurrent Anaplastic Astrocytoma 1
World Health Organization (WHO) Grade III Glioma 1
Spinal Cord Glioma 1
Recurrent Malignant Central Nervous System Neoplasm 1
Recurrent Ependymoma 1
Diffuse Midline Glioma (DMG) 1

What is open in the Sabine Mueller, MD, PhD pipeline

5 recruiting of 12 indexed (42% open); 4 completed (33%).

Phase mix: 0 late (III/IV) vs 12 early (I/II) (early-phase heavy).

Top condition: Recurrent Malignant Glioma (2 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Sabine Mueller, MD, PhD: open-pipeline peers nationwide

Peers matched on 12 registered trials and 42% open enrollment, not the therapeutic-area sidebar.

Sabine Mueller, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 11.911.91212.1 0%10%20%30%40%50% Total trials Recruiting share Sabine Mueller, MD, PhDAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsArthrexDiwakar DavarExactechInari Medical
Sabine Mueller, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Sabine Mueller, MD, PhD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 42% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Sabine Mueller, MD, PhD page

12 registered trials is a research-attention snapshot, not an endorsement of Sabine Mueller, MD, PhD or any single study.

  • 5 of Sabine Mueller, MD, PhD's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Recurrent Malignant Glioma is the condition Sabine Mueller, MD, PhD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Recurrent Malignant Glioma trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Sabine Mueller, MD, PhD pipeline card: 12 registered trials from official public datasets.Report a data error.